BIOのチャート
BIOの企業情報
| symbol | BIO |
|---|---|
| 会社名 | Bio-Rad Laboratories Inc （BIO バイオ・ラッド・ラボラトリ―ズ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 バイオ・ラッド・ラボラトリーズ（Bio-Rad Laboratories Inc.）は複合化学材料及び生物材料の分離またはその成分の識別・分析・浄化に応用される各種製品及びシステムの製造会社である。同社製品は主にライフサイエンス研究、保健及び分析化学等の分野に提供されている。同社はライフサイエンス事業及び臨床診断事業の２つの事業区分により構成される。平成23年12月期決算期において、ライフサイエンス事業及び臨床診断事業の純売上高はそれぞれ同社総純売上高の33%と66%を占めた。平成23年12月期決算期において、ライフサイエンス事業及び臨床診断事業の純売上高はそれぞれ同社の総合純売上高の33%と66%を占めた。平成23年度において、同社の連結売上高の約30％は米国販売事業から、70%は世界中その他市場事業から生じた。平成23年12月31日現在、同社は子会社を通じて、米国以外の35以上の国での直接流通チャネルを所有している。 バイオ・ラッド・ラボラトリ―ズは、米国の医薬品会社。事業は2部門で構成される。ライフサイエンス部門は、実用的なゲノミクス、プロテオミクス、食品安全性の研究に使用される多様な実験用機器、装置、および消耗品の開発、製造、および販売を行う。診断薬部門は、医学的スクリ―ニングおよび診断向けの幅広い製品の開発、製造、販売、およびサポ―トを行う。 bio-rad laboratories (nyse: bio and biob) offers a broad range of innovative tools and services to the life science research and clinical diagnostics markets. founded in 1952, bio-rad has a global team of more than 7,600 employees and serves more than 100,000 research and industry customers worldwide through the company's global network of operations. throughout its existence, bio-rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more. based in hercules, ca, bio-rad has operations worldwide. |
| 本社所在地 | 510 724-7000 |
| 代表者氏名 | Norman D. Schwartz |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer |
| 電話番号 | +1 510-724-7000 |
| 設立年月日 | 1952年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 8260人 |
| url | www.bio-rad.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 345.37900 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 9145.17200 |
| 売上高 | 売上高（百万ドル） 2290.10900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 8734.24600 |
| 当期純利益 | 当期純利益（百万ドル） 311.99600 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Bio-Rad Laboratories Inc. revenues increased 6% to $2.29B. Net income before extraordinary items increased from $52.2M to $312M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Acquisition Cost decrease from $10M (expense) to $0K Restructuring Charges_Provisions decrease of 90% to $855K (expense). |
BIOのテクニカル分析
BIOのニュース
Victory Capital Management Inc. Has $5.03 Million Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) 2023/05/28 10:40:30 The AM Reporter
Victory Capital Management Inc. lifted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO – Get Rating) by 36.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,768 shares of the medical research company’s stock after purchasing an additional 2,898 shares […]
Death Cross Looms Over Bio-Rad Laboratories Investors 2023/05/24 14:48:02 Benzinga
If history is any guide, there may be trouble ahead for shares of Bio-Rad Laboratories (NYSE: BIO ). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses … Full story available on Benzinga.com
Multiplex Assays Market Size 2022 :Industry Growth, Future Demands, Trends, and Forecast to 2027 2023/05/17 13:00:00 SBWire
In September 2021, Bio-Rad Laboratories launched its Bio-Plex Pro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The panels are for research use only (RUO). Northbrook, IL 60062 -- ( SBWIRE ) -- 05/17/2023 -- The multiplex assays industry is expected to experience significant growth in the near future. This is due to the increasing demand for multiplex assays in clinical and research settings. Multiplex assays are an efficient and cost-effective way to analyze multiple biomarkers in a single sample. This technology can be used to diagnose and monitor diseases, assess drug efficacy, and identify potential drug targets. Additionally, multiplex assays can be used to quickly diagnose and monitor infectious diseases, food safety, and environmental contaminants. As the demand for multiplex assays continues to increase, the industry is likely to experience further growth and innovation in the near future. Multiplex Assays Market in terms of revenue was estimated to be worth $3.5 billion in 2022 and is poised to reach $5.3 billion by 2027, growing at a CAGR of 8.8% from 2022 to 2027 according to a new report by MarketsandMarkets™.
Western Blotting Market is Estimated to be Worth US$ 1753.4 Million at a CAGR of 6% by Forecast Period from 2023 to 2033 | Report by Future Market Insights, Inc. 2023/05/16 13:30:00 Accesswire
NEWARK, DE / ACCESSWIRE / May 16, 2023 / The global Western Blotting Market is estimated to attain a valuation of US$ 980.1 Million in 2023 and is anticipated to reach US$ 1753.4 million by 2033, trailing a CAGR of 6% during the forecast period. The growing prevalence of Lyme and Human Immuno Deficiency (HIV) diseases in the region is a significant driver for market growth. Increased research activities, research and development investments by pharmaceutical and biotechnology companies, and advancements in the proteomics sector further contribute to market growth. The rise in industry-academic research collaborations and the growing demand for personalized medicine also play a role in influencing the market. The global Western Blotting market is expected to be driven by the increasing prevalence of HIV during the forecast period, as Western Blotting is predominantly utilized for HIV detection. For example, in January 2022, data from UNAIDS, a Joint United Nations Programme involved in Human Immuno Deficiency epidemiology data collection, indicated that 1.5 Million people were newly infected with HIV in 2021.
RBC Capital maintains Bio-Rad Labs at Outperform with a price target of $531.00 2023/05/08 11:27:37 Investing.com
https://www.investing.com/news/pro/biorad-laboratories-inc-receives-investment-bank-analyst-rating-update-3075704
EASTERLY INVESTMENT PARTNERS LLC Buys 2, Sells 3 in 1st Quarter 2022/08/02 19:00:41 GuruFocus
Related Stocks: NCR , PFE , IBM , BIO , VOD ,
Bio-Rad Laboratories, Inc. (BIO) Management on Q2 2022 Results - Earnings Call Transcript 2022/07/29 01:52:05 Seeking Alpha
Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q2 2022 Earnings Conference Call July 28, 2022 06:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive…
Bio-Rad Laboratories: Q2 Earnings Insights 2022/07/28 22:00:21 Benzinga
Bio-Rad Laboratories (NYSE: BIO ) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Bio-Rad Laboratories beat estimated earnings by 20.71%, reporting an EPS of $3.38 versus an … Full story available on Benzinga.com
Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M 2022/07/28 20:50:37 Seeking Alpha
Bio-Rad Labs press release (BIO): Q2 Non-GAAP EPS of $3.38 beats by $0.67.Revenue of $691.1M (-3.5% Y/Y) beats by $26.5M.For the full-year 2022, the company now anticipates…
Bio-Rad Reports Second-Quarter 2022 Financial Results 2022/07/28 20:17:00 Wallstreet:Online
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compared to $715.9 million reported for the second quarter of 2021. COVID-related revenue was approximately $33 million
Bio-Rad Laboratories, Inc. (BIO) Management on Q2 2022 Results - Earnings Call Transcript 2022/07/29 01:52:05 Seeking Alpha
Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q2 2022 Earnings Conference Call July 28, 2022 06:00 PM ET Company Participants Edward Chung - Head of Investor Relations Ilan Daskal - Executive…
Bio-Rad Laboratories: Q2 Earnings Insights 2022/07/28 22:00:21 Benzinga
Bio-Rad Laboratories (NYSE: BIO ) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Bio-Rad Laboratories beat estimated earnings by 20.71%, reporting an EPS of $3.38 versus an … Full story available on Benzinga.com
Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M 2022/07/28 20:50:37 Seeking Alpha
Bio-Rad Labs press release (BIO): Q2 Non-GAAP EPS of $3.38 beats by $0.67.Revenue of $691.1M (-3.5% Y/Y) beats by $26.5M.For the full-year 2022, the company now anticipates…
Bio-Rad Reports Second-Quarter 2022 Financial Results 2022/07/28 20:17:00 Wallstreet:Online
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compared to $715.9 million reported for the second quarter of 2021. COVID-related revenue was approximately $33 million